Innovative and Articulate: A Buying Opportunity for Spyre Therapeutics Weakness After Teva Data, According to BTIG
BTIG Analyst Highlights Teva’s Enterprise Value Increase Summary: BTIG analyst Julian Harrison notes that Teva’s enterprise value has increased by more than $4B today after Phase 2b UC/CD data of a TL1A asset that “they only own 50% rights to” plus $1B in development and launch milestones. The firm’s “main takeaways” for Spyre Therapeutics (SYRE)…